Hair loss drug offered to patients with no other options
NCT ID NCT05522556
Summary
This program provides early access to the investigational drug ritlecitinib for patients with severe alopecia areata who have lost at least 50% of their scalp hair. It's designed for people who haven't responded well to or can't tolerate other standard treatments available in their country. Doctors can request access for individual patients through Pfizer's compassionate use program.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.